CAJ | 학술논문

目的：探讨草苁蓉乙醇提取物（BREE)对非酒精性脂肪性肝病（NAFLD)大鼠肝组织羟脯氨酸和炎性因子的影响。方法采用高脂饲料喂养构建大鼠 NAFLD 模型，大鼠被随机分为正常对照组、NAFLD 模型组和 BREE治疗组（500 mg·kg-1·d-1）。在用药8 w 末，处死动物，留取血清，采用 ELSIA 法检测肝组织白细胞介素（IL）-1β、肿瘤坏死因子（TNF）-α和白细胞介素（IL）-6水平；采用 HE 染色和免疫组化法分别观察大鼠肝脏病理学变化和检测肝组织 NF-kB/p65表达。结果 BREE 治疗组大鼠血清 ALT [（39.47±20.26）U/L]和 AST[（46.48±18.52）U/L]水平较模型组显著下降[（79.32±19.05）U/L 和（88.35±17.46）U/L，P<0.01]，而血清还原性谷胱甘肽[（349.43±45.52）mg/L]水平较模型组明显升高[（265.38±28.57） mg/L，P<0.01]；BREE 治疗组大鼠肝组织 NF-kB/p65阳性表达[（15.49±4.78）%]和羟脯氨酸含量[（14.28±3.08) mg/g]均较模型组显著下降[分别为（87.54±6.59）%和（35.47±4.53）mg/g，P<0.01]，同样，IL-1β、TNF-α和 IL-6水平[分别为（34.51±5.61） pg/mL、（45.37±7.03）pg/mL）和（18.98±5.04）pg/mL]均较模型组显著降低[分别为（78.25±6.51） pg/mL、（85.64±6.25） pg/mL、（29.19±4.82） pg/mL，P<0.01]；BREE 处理组动物肝组织病理学损害程度明显减轻。结论 BREE 能明显改善 NAFLD 大鼠肝功能和肝组织胶原沉积，其机制可能与通过下调 NF-κB/p65和炎症细胞因子表达有关。
목적：탐토초종용을순제취물（BREE)대비주정성지방성간병（NAFLD)대서간조직간포안산화염성인자적영향。방법채용고지사료위양구건대서 NAFLD 모형，대서피수궤분위정상대조조、NAFLD 모형조화 BREE치료조（500 mg·kg-1·d-1）。재용약8 w 말，처사동물，류취혈청，채용 ELSIA 법검측간조직백세포개소（IL）-1β、종류배사인자（TNF）-α화백세포개소（IL）-6수평；채용 HE 염색화면역조화법분별관찰대서간장병이학변화화검측간조직 NF-kB/p65표체。결과 BREE 치료조대서혈청 ALT [（39.47±20.26）U/L]화 AST[（46.48±18.52）U/L]수평교모형조현저하강[（79.32±19.05）U/L 화（88.35±17.46）U/L，P<0.01]，이혈청환원성곡광감태[（349.43±45.52）mg/L]수평교모형조명현승고[（265.38±28.57） mg/L，P<0.01]；BREE 치료조대서간조직 NF-kB/p65양성표체[（15.49±4.78）%]화간포안산함량[（14.28±3.08) mg/g]균교모형조현저하강[분별위（87.54±6.59）%화（35.47±4.53）mg/g，P<0.01]，동양，IL-1β、TNF-α화 IL-6수평[분별위（34.51±5.61） pg/mL、（45.37±7.03）pg/mL）화（18.98±5.04）pg/mL]균교모형조현저강저[분별위（78.25±6.51） pg/mL、（85.64±6.25） pg/mL、（29.19±4.82） pg/mL，P<0.01]；BREE 처리조동물간조직병이학손해정도명현감경。결론 BREE 능명현개선 NAFLD 대서간공능화간조직효원침적，기궤제가능여통과하조 NF-κB/p65화염증세포인자표체유관。
Objective To investigate the effect of boschniakia rossica ethanol extract (BREE) on hydroxyproline (Hyp) and inflammatory cytokines in rats with non -alcoholic fatty liver diseases (NAFLD). Methods The model of NAFLD in rats was established by hight -fat diet administration. Rats were randomly divided into control,model and BREE treatment group(500 mg·kg-1·d-1). All rats were sacrificed to harvest serum and liver tissues at the end of eighth week. Serum levels of AST,ALT and reduced glutathione (GSH) were measured,and the levels of interleukin (IL)-1β,tumor necrosis factor (TNF)-α and IL-6 in liver tissues were detected by ELSIA. HE staining and immunohistochemistry were performed for evaluation of liver pathological changes and the expression of NF-kB/p65 in liver tissues,respectively. Results Serum levels of ALT [(39.47± 20.26) U/L] and AST [(46.48 ± 18.52) U/L] in rats subjected to BREE treatment significantly decreased as compared to in the model group [(79.32±19.05)U/L and (88.35±17.46) U/L,respectively,P﹤0.01];Serum GSH levels in BREE-treated rats [(349.43±45.52) mg/L] significantly increased than in the model [(265.38±28.57) mg/L,P﹤0.01];The positive rates of NF-kB/p65 [(15.49±4.78)%] and Hyp contents [(14.28±3.08) mg/g] in liver tissues in BREE-treated rats significantly decreased than in the model [(87.54±6.59)% and (35.47±4.53)mg/g, respectively,P﹤0.01];the IL-1β,TNF-α and IL-6 levels [(34.51±5.61) pg/mL,(45.37±7.03) pg/mL,(18.98±5.04) pg/mL,respectively] in liver tissues in BREE-treated rats were significantly lower than in the model [(78.25±6.51) pg/mL,(85.64 ±6.25) pg/mL,(29.19 ±4.82) pg/mL,respectively,P ﹤0.01];BREE also significantly alleviated pathological changes in the liver. Conclusions BREE significantly improves liver function and collagen deposition in rats with NAFLD by down regulation of NF-κB/p65 and inflammatory cytokines in the liver.